Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib

Lung Cancer

Volumn 104, Issue , 2017, Pages 16-23

  Messaritakis, I ^a   Politaki, E ^a   Plataki, M ^a   Karavassilis, V ^c   Kentepozidis, N ^d   Koinis, F ^a,b   Samantas, E ^e   Georgoulias, V ^a,b   Kotsakis, A ^a,b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^d IASO GENERAL HOSPITAL   (Greece)

^e Agioi Anargyroi Anticancer Hospital   (Greece)

Author keywords

CD56; CellSearch; CTCs; Immunofluorescence; Pazopanib; SCLC; TTF 1; VEGFR2

Indexed keywords

CD45 ANTIGEN; CD56 ANTIGEN; CYTOKERATIN; PAZOPANIB; THYROID TRANSCRIPTION FACTOR 1; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; DNA BINDING PROTEIN; KDR PROTEIN, HUMAN; NCAM1 PROTEIN, HUMAN; PTPRC PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TTF1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CELL COUNT; CELL SUBPOPULATION; CIRCULATING TUMOR CELL; CLINICAL OUTCOME; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMALL CELL LUNG CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFECTS; IMMUNOLOGY; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; SMALL CELL LUNG CARCINOMA; TUMOR EMBOLISM; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIGENS, CD45; ANTIGENS, CD56; BIOMARKERS, TUMOR; DNA-BINDING PROTEINS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC CELLS, CIRCULATING; NON-RANDOMIZED CONTROLLED TRIALS AS TOPIC; PYRIMIDINES; SMALL CELL LUNG CARCINOMA; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 85008221886     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.12.008     Document Type: Article

References (50)

1. [1] Jackman, D.M., Johnson, B.E., Small-cell lung cancer. Lancet 366 (2005), 1385–1396.
2. [2] Takada, M., Fukuoka, M., Kawahara, M., Sugiura, T., Yokoyama, A., Yokota, S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J. Clin. Oncol. 20 (2002), 3054–3060.
3. [3] Turrisi, A.T. 3rd, Kim, K., Blum, R., Sause, W.T., Livingston, R.B., Komaki, R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N. Engl. J. Med. 340 (1999), 265–271.
4. [4] Lucchi, M., Mussi, A., Fontanini, G., Faviana, P., Ribechini, A., Angeletti, C.A., Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur. J. Cardiothorac. Surg. 21 (2002), 1105–1110.
5. [5] Stefanou, D., Batistatou, A., Arkoumani, E., Ntzani, E., Agnantis, N.J., Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small-cell lung carcinomas. Histol. Histopathol. 19 (2004), 37–42.
6. [6] Aslam, S., Eisen, T., Vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell cancer: latest results and clinical implications. Ther. Adv. Med. Oncol. 5 (2013), 324–333, 10.1177/1758834013507966.
7. [7] Podar, K., Tonon, G., Sattler, M., Tai, Y.T., Legouill, S., Yasui, H., et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 19478–19483 Epub 12006 Dec 19412.
8. [8] Gupta, S., Spiess, P.E., The prospects of pazopanib in advanced renal cell carcinoma. Ther. Adv. Urol. 5 (2013), 223–232, 10.1177/1756287213495099.
9. [9] Sleijfer, S., Ray-Coquard, I., Papai, Z., Le Cesne, A., Scurr, M., Schoffski, P., et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J. Clin. Oncol. 27 (2009), 3126–3132, 10.1200/JCO.2008.3121.3223 Epub 2009 May, 3118.
10. [10] Cristofanilli, M., Budd, G.T., Ellis, M.J., Stopeck, A., Matera, J., Miller, M.C., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351 (2004), 781–791.
11. [11] de Bono, J.S., Scher, H.I., Montgomery, R.B., Parker, C., Miller, M.C., Tissing, H., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14 (2008), 6302–6309.
12. [12] Hou, J.M., Krebs, M.G., Lancashire, L., Sloane, R., Backen, A., Swain, R.K., et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J. Clin. Oncol. 30 (2012), 525–532.
13. [13] Lecharpentier, A., Vielh, P., Perez-Moreno, P., Planchard, D., Soria, J.C., Farace, F., Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br. J. Cancer 105 (2011), 1338–1341, 10.1038/bjc.2011.1405 Epub 2011 Oct 1334.
14. [14] Stathopoulou, A., Vlachonikolis, I., Mavroudis, D., Perraki, M., Kouroussis, C., Apostolaki, S., et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J. Clin. Oncol. 20 (2002), 3404–3412.
15. [15] Xenidis, N., Perraki, M., Kafousi, M., Apostolaki, S., Bolonaki, I., Stathopoulou, A., et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J. Clin. Oncol. 24 (2006), 3756–3762 Epub 2006 Jun 3712.
16. [16] I.S.D. Messaritakis, E. Politaki, S. Apostolaki, K.E. Dermitzaki, M. Sfakianaki, A. Kotsakis, E. Lagoudaki, D. Mavroudis, J. Souglakos, V. Georgoulias, Detection of Circulating Tumor Cells in the peripheral blood of patients with untreated Small Cell Lung Cancer (SCLC) using both the CellSearch platform and immunofluorescence: correlation with clinico-pathological features In: Advances in Circulating Tumor Cells (ACTC). Rethymnon, Heraklion, Crete, Greece (2014).
17. [17] I.S.D. Messaritakis, K.E. Dermitzaki, P. Koinis, A. Kotsakis, E. Lagoudaki, J. Souglakos, V. Georgoulias, Phenotypic heterogeneity of circulating tumor cells in patients with small cell lung cancer (SCLC). submitted for publication (2016).
18. [18] Hiltermann, T.J., Pore, M.M., van den Berg, A., Timens, W., Boezen, H.M., Liesker, J.J., et al. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann. Oncol. 23 (2012), 2937–2942.
19. [19] Igawa, S., Gohda, K., Fukui, T., Ryuge, S., Otani, S., Masago, A., et al. Circulating tumor cells as a prognostic factor in patients with small cell lung cancer. Oncol. Lett. 7 (2014), 1469–1473.
20. [20] Normanno, N., Rossi, A., Morabito, A., Signoriello, S., Bevilacqua, S., Di Maio, M., et al. Prognostic value of circulating tumor cells’ reduction in patients with extensive small-cell lung cancer. Lung Cancer 85 (2014), 314–319.
21. [21] I. Messaritakis, D. Stoltidis, E. Politaki, S. Apostolaki, K.E. Dermitzaki, M. Sfakianaki, A. Kotsakis, E. Lagoudaki, D. Mavroudis, J. Souglakos, V. Georgoulias, Detection of Circulating Tumor Cells in the peripheral blood of patients with untreated Small Cell Lung Cancer (SCLC) using both the CellSearch platform and immunofluorescence: correlation with clinico-pathological features In: Advances in Circulating Tumor Cells (ACTC) Rethymnon, Heraklion, Crete, Greece (2014).
22. [22] Di Loreto, C., Di Lauro, V., Puglisi, F., Damante, G., Fabbro, D., Beltrami, C.A., Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma. J. Clin. Pathol. 50 (1997), 30–32.
23. [23] Folpe, A.L., Gown, A.M., Lamps, L.W., Garcia, R., Dail, D.H., Zarbo, R.J., et al. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod. Pathol. 12 (1999), 5–8.
24. [24] Haque, A.K., Syed, S., Lele, S.M., Freeman, D.H., Adegboyega, P.A., Immunohistochemical study of thyroid transcription factor-1 and HER2/neu in non-small cell lung cancer: strong thyroid transcription factor-1 expression predicts better survival. Appl. Immunohistochem. Mol. Morphol. 10 (2002), 103–109.
25. [25] Ordonez, N.G., Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am. J. Surg. Pathol. 24 (2000), 598–606.
26. [26] Travis, W.D., Advances in neuroendocrine lung tumors. Ann. Oncol. 21:Suppl. 7 (2010), vii65–vii71.
27. [27] Yatabe, Y., Mitsudomi, T., Takahashi, T., TTF-1 expression in pulmonary adenocarcinomas. Am. J. Surg. Pathol. 26 (2002), 767–773.
28. [28] Zamecnik, J., Kodet, R., Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: a study of 109 cases. Virchows Arch. 440 (2002), 353–361.
29. [29] Kontogianni, K., Nicholson, A.G., Butcher, D., Sheppard, M.N., CD56: a useful tool for the diagnosis of small cell lung carcinomas on biopsies with extensive crush artefact. J. Clin. Pathol. 58 (2005), 978–980.
30. [30] Stovold, R., Blackhall, F., Meredith, S., Hou, J., Dive, C., White, A., Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells. Lung Cancer 76 (2012), 263–268, 10.1016/j.lungcan.2011.1011.1015 Epub 2011 Dec 1015.
31. [31] Stovold, R., Meredith, S.L., Bryant, J.L., Babur, M., Williams, K.J., Dean, E.J., et al. Neuroendocrine and epithelial phenotypes in small-cell lung cancer: implications for metastasis and survival in patients. Br. J. Cancer 108 (2013), 1704–1711, 10.1038/bjc.2013.1112 Epub 2013 Mar 1721.
32. [32] Cohen, S.J., Punt, C.J., Iannotti, N., Saidman, B.H., Sabbath, K.D., Gabrail, N.Y., et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26 (2008), 3213–3221.
33. [33] Krebs, M.G., Sloane, R., Priest, L., Lancashire, L., Hou, J.M., Greystoke, A., et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J. Clin. Oncol. 29 (2011), 1556–1563.
34. [34] Bozionellou, V., Mavroudis, D., Perraki, M., Papadopoulos, S., Apostolaki, S., Stathopoulos, E., et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin. Cancer Res. 10 (2004), 8185–8194.
35. [35] Georgoulias, V., Bozionelou, V., Agelaki, S., Perraki, M., Apostolaki, S., Kallergi, G., et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Ann. Oncol. 23 (2012), 1744–1750, 10.1093/annonc/mds1020 Epub 2012 Feb 1729.
36. [36] Kallergi, G., Agelaki, S., Papadaki, M.A., Nasias, D., Matikas, A., Mavroudis, D., et al. Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. Breast Cancer Res., 17, 2015, 113, 10.1186/s13058-13015-10624-x.
37. [37] Kalykaki, A., Agelaki, S., Kallergi, G., Xyrafas, A., Mavroudis, D., Georgoulias, V., Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib. Cancer Chemother. Pharmacol. 73 (2014), 685–693, 10.1007/s00280-00014-02387-y Epub 02014 Feb 00284.
38. [38] Saloustros, E., Perraki, M., Apostolaki, S., Kallergi, G., Xyrafas, A., Kalbakis, K., et al. Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. Breast Cancer Res., 13, 2011, R60.
39. [39] Xenidis, N., Ignatiadis, M., Apostolaki, S., Perraki, M., Kalbakis, K., Agelaki, S., et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J. Clin. Oncol. 27 (2009), 2177–2184.
40. [40] Xenidis, N., Perraki, M., Apostolaki, S., Agelaki, S., Kalbakis, K., Vardakis, N., et al. Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer. Br. J. Cancer 108 (2013), 549–556.
41. [41] Xenidis, N., Vlachonikolis, I., Mavroudis, D., Perraki, M., Stathopoulou, A., Malamos, N., et al. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann. Oncol. 14 (2003), 849–855.
42. [42] Klein, C.A., Blankenstein, T.J., Schmidt-Kittler, O., Petronio, M., Polzer, B., Stoecklein, N.H., et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360 (2002), 683–689.
43. [43] Kallergi, G., Mavroudis, D., Georgoulias, V., Stournaras, C., Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Mol. Med. 13 (2007), 79–88.
44. [44] Pantel, K., Dickmanns, A., Zippelius, A., Klein, C., Shi, J., Hoechtlen-Vollmar, W., et al. Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines. J. Natl. Cancer Inst. 87 (1995), 1162–1168.
45. [45] Pierga, J.Y., Bonneton, C., Magdelenat, H., Vincent-Salomon, A., Nos, C., Pouillart, P., et al. Clinical significance of proliferative potential of occult metastatic cells in bone marrow of patients with breast cancer. Br. J. Cancer 89 (2003), 539–545.
46. [46] Kallergi, G., Markomanolaki, H., Giannoukaraki, V., Papadaki, M.A., Strati, A., Lianidou, E.S., et al. Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res., 11, 2009, R84, 10.1186/bcr2452 Epub 2009 Nov 1117.
47. [47] Buczek, M., Escudier, B., Bartnik, E., Szczylik, C., Czarnecka, A., Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms. Biochim. Biophys. Acta 1845 (2014), 31–41, 10.1016/j.bbcan.2013.1010.1001 Epub 2013 Oct 1014.
48. [48] Khattak, M., Larkin, J., Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance. World J. Urol. 32 (2014), 19–29, 10.1007/s00345-00012-01013-z Epub 02013 Jan 00348.
49. [49] Cho, I.C., Chung, J., Current status of targeted therapy for advanced renal cell carcinoma. Korean J. Urol. 53 (2012), 217–228, 10.4111/kju.2012.4153.4114.4217 Epub 2012 Apr 4118.
50. [50] Gotink, K.J., Verheul, H.M., Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?. Angiogenesis 13 (2010), 1–14, 10.1007/s10456-10009-19160-10456 Epub 12009 Dec 10411.